Emblation, the global leader in medical microwave technology, is thrilled to announce the successful acquisition of Saorsa Inc., its esteemed US distributor. This strategic move is designed to accelerate Emblation's growth trajectory in the United States, particularly in expanding the reach of its renowned Swift® Microwave Therapy technology.
Founded in 2018, Saorsa Inc. has served as the exclusive supplier of Emblation’s Swift system in the United States. Led by medical industry leaders Chris McNamara and Pete Turnbull, Saorsa Inc. has established a stellar reputation and a robust sales network across the country.
Swift® is the pioneering microwave therapy treatment for skin. With treatment times in seconds, Swift® provides Podiatrists and Dermatologists with a new, precise, and easy procedure for soft tissue lesions.
The Swift® treatment method delivers a controlled dose of energy into the tissue, triggering heat and stimulating an immune response. This approach mitigates risks associated with destructive modalities while delivering highly effective outcomes for stubborn skin lesions.
Gary Beale, Emblation CEO, commented, "the acquisition of Saorsa represents another step forward in our scale-up plans and will contribute significantly to achieving our commercial and clinical goals. We have known the team personally for more than a decade and have worked closely on the US market strategy for our Swift technology since 2018. It’s a real pleasure to welcome them to the Emblation global family.”
Chris MacNamara, co-founder of Saorsa Inc. added: “We are excited and energized to be officially joining the Emblation group. This acquisition was an important step for both companies to achieve our collective long-term ambition to establish Swift as the market leader in microwave-based applications for skin lesions. We will be able to immediately leverage shared capabilities and will sharpen our focus on further resourcing the US business for accelerated growth.”
UK & Ireland 
Deutschland 
United States 